Navigation Links
Study Evaluated Vyvanse® (lisdexamfetamine dimesylate) Capsules CII Efficacy and Safety in Adolescents with ADHD
Date:5/25/2010

NEW ORLEANS, May 25 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today announced the results of a study evaluating the safety and efficacy of Vyvanse® (lisdexamfetamine dimesylate) Capsules CII for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adolescents aged 13 to 17 years.  The data, presented in an oral session at a national scientific meeting of psychiatrists in New Orleans, LA, demonstrated that treatment with Vyvanse (30, 50, and 70 mg/d) significantly improved ADHD symptoms compared to placebo in adolescents with ADHD.

Vyvanse is currently indicated for the treatment of ADHD in children aged 6 to 12 years and in adults.  Recently, Shire submitted a supplemental New Drug Application (sNDA) for use of Vyvanse in the treatment
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Kline Study: Better Brushing Habits Boost European Oral Care Sales
4. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
5. NASA study will help stop stowaways to Mars
6. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
7. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
8. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
9. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
10. Quigley Corporation Releases Update on Quigley Pharmas Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
11. Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... -- Theravalues Corporation est fier d,annoncer le lancement ... salon Hi Europe 2014 (du 2 au 4 décembre ... Curcumine la plus biodisponible actuellement sur le marché, ... ingrédients approuvés par les règlements européens. ... la racine de curcuma ( Curcuma longa ) ...
(Date:11/26/2014)... novembre 2014 /PRNewswrie/ -- Theravalues Corporation annuncia con orgoglio ... in occasione di Hi Europe 2014 (dal 2 al ... Si tratta della curcumina con la maggiore biodisponibilità di ... e ingredienti approvati dalle norme europee. La ... pianta curcumina ( Curcuma longa ) che è stata ...
(Date:11/24/2014)... , Nov. 24, 2014  IGI Laboratories, Inc. (NYSE ... based specialty generic pharmaceutical company, today announced it has ... the U.S. Food and Drug Administration (FDA), which brings ... to seven, with eighteen submissions now pending at the ... and CEO of the Company, commented, "Our team here ...
(Date:11/24/2014)... , Nov. 24, 2014  Last week, Representatives ... Butterfield (D-NC) took a bold bipartisan step ... introducing the OPEN Act. Original co-sponsors of the ... The Act will incentivize drug makers and innovators ... diseases and pediatric cancers, which opens the door ...
Breaking Biology Technology:La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 2La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 3La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 2La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 3IGI Laboratories, Inc. Announces ANDA Submission 2OPEN Act Introduced to Repurpose Drugs for Rare Diseases 2
... Inc. announced today that David J. Mazzo, Ph.D., President ... 27th Annual J.P. Morgan Healthcare Conference in San Francisco, ... Time (2:30pm Eastern Time). Dr. Mazzo,s presentation will ... development, the REG1 System, its pipeline and enterprise-level business ...
... Dedicated to the memory and scientific accomplishments of Dr. Judah ... shed light on the link between blood supply and neoplastic ... 3-4) of Lymphatic Research and Biology ... of one of the pre-eminent physician-scientists of his generation. ...
... Ill., Jan. 6 Horizon Therapeutics, Inc., a,privately ... Grahn to vice president, clinical operations and Iain ... "Amy and Iain bring valuable ... filings in the U.S. and Europe and move ...
Cached Biology Technology:Festschrift Issue Honoring Judah Folkman, M.D. in Lymphatic Research and Biology 2Festschrift Issue Honoring Judah Folkman, M.D. in Lymphatic Research and Biology 3Horizon Therapeutics Announces Senior Management Appointments 2Horizon Therapeutics Announces Senior Management Appointments 3
(Date:11/5/2014)... Redmond has dedicated his career to understanding the ... general audience. , As deputy director and regional ... Nevada,s Desert Research Institute, Redmond has more than ... and dissemination of climate data to the general ... in San Francisco on December 15-19, 2014 the ...
(Date:11/4/2014)... of Medicine announced today that it is a ... the Bill & Melinda Gates Foundation. Laura ... Reproductive Sciences; and Vice Chair of Research and ... will pursue an innovative global health and development ... Fetal Neurodevelopment.", Grand Challenges Explorations (GCE) funds individuals ...
(Date:11/4/2014)... – A majority of Madagascar,s 101 species of lemurs ... consequences for the rainforests they call home. A new ... lemurs can have on rainforest tree populations, which raises ... on the region,s rich biodiversity. , A large proportion ... lemurs. Lemurs in turn disperse the seeds of ...
Breaking Biology News(10 mins):Nevada climatologist to be honored at AGU Fall Meeting for lifetime of public outreach 2Temple University School of Medicine receives Grand Challenges Explorations grant 2Gardeners of Madagascar rainforest at risk 2Gardeners of Madagascar rainforest at risk 3
... Troy, N.Y. The purification of drug components is ... particularly true of drugs that utilize proteins, which are ... Scientists within the Center for Biotechnology and Interdisciplinary Studies ... resonance (NMR) to understand and improve an important protein ...
... to anchor teeth back in the jaw using stem cells ... the first time by researchers at the University of Illinois ... advance in the battle against gum disease, a serious infection ... U.S. adults suffer from gum disease, according to the National ...
... recent human trials for a promising new class of ... without shutting down the immune system, some of the ... In response, an interdisciplinary team of Florida State ... genetic screening method that can identify the drug-resistant HCV ...
Cached Biology News:Purifying proteins: Rensselaer researchers use NMR to improve drug development 2Purifying proteins: Rensselaer researchers use NMR to improve drug development 3Technique to reattach teeth using stem cells developed at UIC 2Hepatitis C virus faces new weapon from Florida State scientists 2Hepatitis C virus faces new weapon from Florida State scientists 3
See product name for description....
... PhastGel DNA Silver Staining Kit, ... polyacrylamide gels.Separate proteins and peptides on ... time and improve reproducibility with precast ... detection sensitivity comparable to that of ...
RAT ANTI MOUSE TCR V BETA 7:RPE Immunogen: T-cell lymphoma TK1...
Human HAPLN1 MAb (Clone 316119) Protein Family: Hyaluronan (HA) & HA Binding Proteins, Proteoglycan Regulators...
Biology Products: